NL-OMON30852已完成4 期
A randomised, double blind placebo controlled trial to (A) assess the optimal vitamin K dosage for supplementation, and (B) to access wether complications of anticoagulation treatment will diminish by suppletion of vitamin K. - VIKS-2A / VIKS-2B
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 2,600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Start treatment with vitamin K antagonists less then 4 weeks before inclusion.
- •2. Treatment with vitamin K antagonists for a minimal period of 6 months, with the therapeutic range of INR between 2.5 and 3.5.
- •3. Age between 18 and 85 years.
- •4. Measurement of the INR by the Thrombosis Service Leiden.
- •5. Informed consent.
排除标准
- •1. Treatment for liver failure.
- •2. Dialysys, both peritoneal as hemodialysys.
- •3. Pregnancy or wish to get pregnant, lactational period.
- •4. Known to have a chronic condition with a life expectancy of less than 6 months.
- •5. An expected interruption of treatment with oral anticoagulants for one week or longer.
- •6. Participation of the self management protocol.
研究者
相似试验
进行中（未招募）
不适用
A randomised, double blind placebo controlled trial to (A) assess the optimal vitamin K dosage for supplementation, and (B) to access whether complications of anticoagulation treatment will diminish by supplementation of vitamin K: VIKS-2A / VIKS-2B. - VIKS-2A / VIKS-2BEUCTR2007-004578-15-NLDutch Heart Foundation2,600
已完成
不适用
A study of AMLA extract to assess the antioxidant and rejuvenation potential in adults in a placebo controlled clinical trial.CTRI/2018/08/015157Acara Bioherb Pvt Ltd
进行中（未招募）
1 期
TWICS - Theophylline with Inhaled CorticosteroidsEUCTR2013-001490-25-GBniversity of Aberdeen1,424
进行中（未招募）
1 期
Bisoprolol in COPD Study (BICS)EUCTR2017-002779-24-GBniversity of Aberdeen1,574
已完成
不适用
Randomised, double-blinded placebo controlled trial of the use of tocolysis for a repeat external cephalic version after a failed version for breech presentation at termChildbirthPregnancy and ChildbirthOther assisted single deliveryISRCTN31614268HS R&D Regional Programme Register - Department of Health (UK)124